The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?
- 1 July 2021
- journal article
- research article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 52, 102968
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemicMultiple Sclerosis and Related Disorders, 2020
- Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, SpainMultiple Sclerosis and Related Disorders, 2020
- Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?Journal of the European Academy of Dermatology and Venereology, 2020
- Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable TherapiesJAMA Neurology, 2020
- Disease-modifying therapies and infectious risks in multiple sclerosisNature Reviews Neurology, 2016
- Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 YearsThe Journal of Rheumatology, 2015
- Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequityNeurology, 2014
- Clinical prognostic factors in multiple sclerosis: a natural history reviewNature Reviews Neurology, 2009
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple SclerosisNew England Journal of Medicine, 2008
- Multiple Sclerosis Severity ScoreNeurology, 2005